ECSP11011516A - Inyección de diacetato de ipamorelin y soluciones de la infusión - Google Patents

Inyección de diacetato de ipamorelin y soluciones de la infusión

Info

Publication number
ECSP11011516A
ECSP11011516A ECSP11011516A ECSP11011516A EC SP11011516 A ECSP11011516 A EC SP11011516A EC SP11011516 A ECSP11011516 A EC SP11011516A EC SP11011516 A ECSP11011516 A EC SP11011516A
Authority
EC
Ecuador
Prior art keywords
ipamorelin
injection
infusion solutions
diacetate
acetic acid
Prior art date
Application number
Other languages
English (en)
Inventor
Riccardo Braglia
Rubio Silvina Garcia
Daniel Beidler
Helle Weibel
Original Assignee
Helsinn Therapeutics Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011516(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Therapeutics Us Inc filed Critical Helsinn Therapeutics Us Inc
Publication of ECSP11011516A publication Critical patent/ECSP11011516A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Abstract

Soluciones de la inyección y de la infusión de ipamorelin que tienen la siguiente composición: a) ipamorelin solubilizado por aproximadamente dos equivalentes molares de ácido acético (diacetato de ipamorelin), en una cantidad a partir de 0.001 al 20%, basada en el peso de la base libre del ipamorelin;b) un exceso molar de ácido, preferiblemente ácido acético, en cantidad suficiente para dar un pH de por lo menos 3 y menos de 7; c) opcionalmente a partir de 0.1 al 30% de una o más ayudas de la formulación; yd) agua q.s. al 100%; todos los porcentajes basados en el peso total de la solución.
ECSP11011516 2009-06-12 2011-12-12 Inyección de diacetato de ipamorelin y soluciones de la infusión ECSP11011516A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18659509P 2009-06-12 2009-06-12

Publications (1)

Publication Number Publication Date
ECSP11011516A true ECSP11011516A (es) 2012-03-30

Family

ID=42272260

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP11011516 ECSP11011516A (es) 2009-06-12 2011-12-12 Inyección de diacetato de ipamorelin y soluciones de la infusión

Country Status (24)

Country Link
US (1) US20100317581A1 (es)
EP (1) EP2440180B1 (es)
JP (1) JP2012529510A (es)
KR (1) KR20120030530A (es)
CN (1) CN102481251A (es)
AU (1) AU2010259102B2 (es)
BR (1) BRPI1012931A2 (es)
CA (1) CA2765233A1 (es)
CL (1) CL2011003131A1 (es)
CO (1) CO6470880A2 (es)
CR (1) CR20110618A (es)
CU (1) CU20110232A7 (es)
DO (1) DOP2011000383A (es)
EA (1) EA201270011A1 (es)
EC (1) ECSP11011516A (es)
GT (1) GT201100318A (es)
MX (1) MX2011013113A (es)
NI (1) NI201100212A (es)
NZ (1) NZ596641A (es)
PE (1) PE20121064A1 (es)
SG (1) SG176717A1 (es)
TW (1) TW201106961A (es)
UA (1) UA104762C2 (es)
WO (1) WO2010144265A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6193017B2 (ja) * 2013-06-28 2017-09-06 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ
JP6562902B2 (ja) 2014-03-28 2019-08-21 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281963B6 (sk) * 1993-12-23 2001-09-11 Novo Nordisk A/S Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie
JP2003501394A (ja) * 1999-06-04 2003-01-14 ノボ ノルディスク アクティーゼルスカブ 延長された重度の疾患の異化状態の処理のための組成物
US8263551B2 (en) * 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
WO2009082426A1 (en) * 2007-12-21 2009-07-02 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну

Also Published As

Publication number Publication date
EP2440180B1 (en) 2014-08-27
AU2010259102A1 (en) 2012-01-12
JP2012529510A (ja) 2012-11-22
KR20120030530A (ko) 2012-03-28
UA104762C2 (ru) 2014-03-11
NI201100212A (es) 2012-04-11
EP2440180A2 (en) 2012-04-18
TW201106961A (en) 2011-03-01
US20100317581A1 (en) 2010-12-16
PE20121064A1 (es) 2012-09-03
EA201270011A1 (ru) 2012-05-30
CA2765233A1 (en) 2010-12-16
DOP2011000383A (es) 2012-05-31
CN102481251A (zh) 2012-05-30
SG176717A1 (en) 2012-01-30
CR20110618A (es) 2012-03-02
GT201100318A (es) 2014-10-13
CO6470880A2 (es) 2012-06-29
WO2010144265A3 (en) 2011-11-24
MX2011013113A (es) 2012-02-21
BRPI1012931A2 (pt) 2018-01-30
WO2010144265A2 (en) 2010-12-16
CU20110232A7 (es) 2012-06-21
CL2011003131A1 (es) 2012-08-17
NZ596641A (en) 2013-12-20
AU2010259102B2 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
PE20130396A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
CY1119269T1 (el) Θεραπεια βλαβων που προκαλουνται απο ιους
UA105229C2 (uk) Фармацевтичний склад
AR081983A1 (es) Articulo de dosis unitaria soluble que comprende un polimero cationico
BR112014017169A8 (pt) máquina de bebidas com módulo removível
UY32731A (es) Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos
MY151295A (en) Pyrimidyl indoline compound
CY1123398T1 (el) Συνθεση συνδυασμου
AR059097A1 (es) Tratamiento a largo plazo de la infeccion por vih
IN2012DN00765A (es)
BR112014006248A2 (pt) compostos de triazolopiridina como inibidores de pde10a
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
RS53783B1 (en) INHALATION MEDICINAL PRODUCTS INCLUDING TIOTROPIUM
WO2014020405A8 (en) Cyclic urea- or lactam-substituted quinoxaline-type piperidine compounds and the uses thereof
ECSP11011516A (es) Inyección de diacetato de ipamorelin y soluciones de la infusión
CO6310996A2 (es) Composicion fungicida que contiene un compuesto de imidazol en combinación con polioxinas
AR083337A1 (es) Tratamientos de infeccion por el virus de hepatitis c
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
ECSP10010701A (es) Formulación farmaceutica de eprosartan
TR200802061A2 (tr) Yüksek oranda aktif madde içeren farmasötlk formülasyon.
JP2011093891A5 (es)
TR201105424A2 (tr) Çinko etken maddeli bir farmasötik formülasyon.
RU2010126053A (ru) Применение аналогов соматостатина при менингиоме
UA98535C2 (uk) Гідрохлориди 1-алкокси-3-діалкіламіно-2-пропанолу
TR200806302A2 (tr) Çözünürlük ve stabilite artırıcı farmasötik formülasyon.